Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SOAT2 | O75908 | 6/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 6/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148506 | 1.00 | MAPT (0.57) | MAPTPOLBEPHX1ALDH1A1HTT | |
| SCHEMBL4127315 | 1.00 | MAPT (0.57) | MAPTPOLBEPHX1ALDH1A1HTT | |
| SCHEMBL4148523 | 1.00 | MAPT (0.57) | MAPTPOLBEPHX1ALDH1A1HTT | |
| SCHEMBL1865256 | 0.83 | SOAT1 (0.77) | MAPTPOLBRAB9ASOAT2SOAT1 | |
| SCHEMBL13678994 | 0.80 | SOAT1 (0.65) | MAPTPOLBALDH1A1RAB9ASOAT2 | |
| SCHEMBL4132285 | 0.80 | MEN1 (0.58) | EPHX1ALDH1A1HTT | |
| SCHEMBL4132087 | 0.80 | MEN1 (0.58) | EPHX1ALDH1A1HTT | |
| SCHEMBL4127216 | 0.80 | MEN1 (0.58) | EPHX1ALDH1A1HTT | |
| SCHEMBL4137645 | 0.80 | MEN1 (0.58) | EPHX1ALDH1A1HTT | |
| SCHEMBL4145849 | 0.80 | MEN1 (0.58) | EPHX1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | MAPT 3184/4885POLB 1144/4885EPHX1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.